Stockholm, Sweden (Press Release) – XNK Thera­peutics AB ("XNK") to­day an­nounced it has re­ceived Orphan Drug Desig­na­tion (ODD) from the U.S. Food and Drug Admin­istra­tion (FDA) for its lead­ing inves­ti­ga­tional drug can­di­date in the treat­ment of mul­ti­ple myeloma (MM).

Receiving ODD status from the FDA for the treat­ment of mul­ti­ple myeloma is a crit­i­cal next step for the de­vel­op­ment of XNK's lead­ing inves­ti­ga­tional drug can­di­date. XNK has already re­ceived ODD status in the EU.

"Obtaining an ODD by the FDA is a sig­nif­i­cant mile­stone for XNK and our goal of taking the present …

Stockholm, Sweden (Press Release) – CellProtect Nordic Pharma­ceu­ticals AB ('CPNP') has been notified by the Euro­pean Com­mis­sion that its cell ther­apy can­di­date CellProtect has re­ceived orphan drug desig­na­tion for the treat­ment of mul­ti­ple myeloma. CellProtect is manu­fac­tured from the patient's own blood and is the first drug can­di­date, con­sist­ing of au­tol­o­gous ex vivo activated and ex­panded nat­u­ral killer (NK) cells, which has re­ceived such desig­na­tion in Europe.

CPNP has carried out a clin­i­cal phase I/II trial in patients with mul­ti­ple myeloma where CellProtect has been studied as a supple­mental treat­ment to au­tol­o­gous stem …